cyrilzakka/clinical-trials huggingface dataset:
Teledi@Log - Tele-rehabilitation of Heart Patients

The idea behind the Teledi@log consortium is to develop tele-rehabilitation concepts and technologies so that all types of heart disease patients, regardless of degree of severity, can be offered individual, customized and coordinated tele-rehabilitation across sectors. The project is innovative, breaking new ground in relation to existing national and international research projects in the area. The Teledi@log consortium sees its major task as developing and testing scenarios which can lead to a more coherent rehabilitation for heart patients in areas such as patient training, organization across the boundaries of the health system and using tele-rehabilitation technology. The Teledi@log consortium seeks to develop new tele-rehabilitation concepts which bring the patient closer to the health system and thereby promote the heart patient's rehabilitation, giving the patient and their families a more active role via new tele-rehabilitation technologies.The hypothesis of the study is that heart patients participating in a telerehabilitation program will have a higher quality of life compared to heart patients following traditional rehabilitation activities.

The aims of the research project are:

To assess the heart patients' and family members' needs for rehabilitation in the health system

To assess the need for coordination of the rehabilitation effort in the health system

To develop tele-rehabilitation concepts and technologies for heart patients, family members and health professionals in the health sector

To promote an early, rapid and effective rehabilitation of heart patients to improve their daily life and working life.

To prevent re-hospitalization of heart patients through a more individualized and differentiated rehabilitation effort using tele-rehabilitation technologies.

To conduct a randomized study of a tele-rehabilitation concept using tele-rehabilitation technologies and to assess the clinical, technical, organizational and health-economic effects.

Eligibility Criteria:
Inclusion Criteria:

* Women and men above 18 years
* Must have signed the "Informed Consent" document
* Must be able to understand study information
* Must live in Hjørring or Frederikshavn Kommune
* Must have mobile network
* Must be able to use IT or have a near person who can use IT
* Patients with clinical diagnosis of Heart Failure, Myocardial Infarction, Angina Pectoris, patients who have had Coronary-Artery Bypass Surgery.

Exclusion Criteria:

* Patients who, according to investigator, will not be able to participate in the study
* Lack of ability to speak and understand Danish
* Pregnancy or nursing
* Neurologic disease
* Use of wheelchair/lack of ability to walk
* Participation in other studies which can influence the outcomes of this study
A Pilot Study to Explore the Role of Gut Flora in Eczema

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding eczema.

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding eczema.

Eligibility Criteria:
Inclusion Criteria:

1. Signed informed consent by patient
2. Male or female patients age 18 and older.
3. Diagnosis of eczema

Exclusion Criteria:

1. Refusal by patient to sign informed consent form
2. Treatment with antibiotics within 2 weeks prior to screening
3. Treatment with probiotics within 6 weeks prior to screening
4. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
5. Postoperative stoma, ostomy, or ileoanal pouch
6. Participation in any experimental drug protocol within the past 12 weeks
7. Treatment with total parenteral nutrition
8. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
9. Inability of patient to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire stud
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study group 1996).


Eligibility Criteria:
Inclusion Criteria:

* Clinically disease-registered for at least one year, leading to consult (abnormal movements, neuropsychiatric disorders, neuropsychological impairment).
* Unified Huntington's Disease Rating Scale motor ≥ 5
* Total Functional Capacity \> 10 (≥ 11)
* Huntington Disease diagnosed with abnormal number of CAG repeats: 38 \< nucleotide expansion (CAG)
* Age between 18 and 65
* Voluntarily Patient Consent
* Patients willing and able to take oral medications, and comply with the specific procedures of the study

Exclusion Criteria:

* Severe cognitive impairment or neuropsychiatric troubles.
* No drug compliance to previous treatment.
* Patients with contra indication to the realization of imaging studies (including claustrophobia ) .
* Patients who have not given their written and informed consent signed .
* No national health insurance affiliation
* Private patients of their liberty by judicial or administrative decision, or patients under supervision.
* Pregnant women ( pregnancy test will be carried out systematically for women at risk) or lactating .
* Women who could become pregnant during the study period and with no contraception.
* Patients who have developed hypersensitivity to cysteamine or penicillamine ( against indication of cysteamine ) .
* Brain Damage intercurrent MRI. Brain morphological abnormalities , other than those characteristic of the disease .
* Disease - associated with neurological repercussions.
* Affection - visceral serious , scalable , involving life-threatening.
* Mental - disorder may disrupt accession to the Protocol , including a history of spontaneous and / or drug-induced hallucinations history of severe depression that required repeated hospitalizations , history of repeated suicide attempts .
* Participation in progress, or interrupted for less than three months, a therapeutic protocol of Huntington's disease .
* Patients with a history of surgical interventions to improve the symptoms of Huntington 's disease such as graft neuron, deep brain stimulation, infusion of neurotrophic agent
Correlation BIS Scores Mentally Retarded Patients

The BIS monitor is a tool which assists anesthesiologists in monitoring the depth of anesthesia or level of anesthesia. The study doctors would like to see if it is useful tool for patients who are mentally challenged and require anesthesia.

General endotracheal tube anesthesia (GETA) is administered for mentally retarded patients that need dental rehabilitation. GETA is done, in all patients, with routine monitoring of electrocardiography, blood pressure recording, pulse oximetry and end-tidal capnography. These measurements are also used indirectly to determine the depth of anesthesia and the anesthetic is titrated to prevent awareness during surgery and any subsequent recall (1). In addition, a recently introduced functional electroencephalography (EEG)-based awareness monitor directly analyzes the brain wave pattern during anesthetic delivery and aids the anesthesiologist in maintaining the ideal depth of anesthesia. The EEG based monitor serves to prevent awareness and recall due to light anesthesia or prolonged recovery following deep anesthesia (2). This instrument, named the Bispectral Index Scale (BIS) monitor, is non-invasive and is approved by the Food \& Drug Administration. However, the BIS monitor is not being used routinely during the anesthetic management of mentally retarded patients due to a belief that such monitoring would be inaccurate in this cohort of patients (3). This assumption lacks scientific validation. Our trial will investigate the usefulness of BIS monitoring in mentally retarded patients and document any correlation between the severity of mental retardation and BIS scoring during various phases of anesthesia, such as awake status and sedation prior to anesthesia, induction and maintenance of anesthesia, and emergence and recovery from anesthesia. The anesthetic protocol will be standardized and the anesthetic management will not deviate from routine practice. The adjuvant therapies for infection prophylaxis and pain control will be administered in the usual fashion.

Eligibility Criteria:
Inclusion Criteria:

* mentally retarded persons ages 12 to 65 undergoing dental rehabilitation

Exclusion Criteria:

* patients who are pregnant parents/and or legal guardians who do not wish to give consent
Medtronic Observational Study in the "Real World" of Implantable Electronic Cardiac Devices

The Observational Study in the "Real World" of Implantable Electronic Cardiac Devices will enable the construction of an electronic database with local access to clinical information, which will collect and disseminate epidemiologic data on demography, cardiovascular mortality and morbidity, and potential risk factors for a selected group of patients. These clinical variables will be analyzed against the data, as based in the programming of devices and the diagnostics. Approved descriptive statistics and analyses will be made available via Internet. The study will describe statistical indexes on sub-groups representing more than 10% of total of datasets.

The study will be open to include any patient that had a Medtronic electronic device implanted, pacemakers, ICD, ICD with CRP. The study will be also adapted for devices implanted in the present and for devices to be implanted in patients in the future.

This study is a Prospective, Multicenter Observational Post Market Release Study. It shall involve around 2,000 patients that are eligible for Implantable Cardiac Pacemakers (IPG) implantation, 500 patients eligible for Cardiac Resynchronization Pacemakers (CRT-P) implantation, 1,000 patients eligible for the implantation of Implantable Cardioverter Defibrillators with or without Cardiac Resynchronization Pacemakers (CDI, CRT-D), and around 20 centers in Brazil. Patients will be consecutively enrolled in centers among those selected for the implantation of a Medtronic device in accordance with indications approved.

Eligibility Criteria:
Inclusion Criteria:

* Patients older than18 years of age
* Patient agrees to participate in the study and is able to sign the Data Release Form
* High probability of adherence to follow-up requirements

Exclusion Criteria:

* Patients who want to be enrolled in another clinical study during at the same time that he/she is part of OBSERVE study.
Chest Imaging, Breath, and Biomarkers in a Screening Trial

The investigators would like to see if lung cancer screening with chest x-rays,computer aided detection (CAD)and a lose dose CT scan can detect lung cancer in early stages when it is more responsive to treatment. The investigators would also like to see if early detection will reduce the incidence of symptomatic advanced lung cancer compared to no screening in former and current smokers with or without a family history of lung cancer who are 40-75 years old.

The fight against lung cancer is waged on three major fronts: prevention, detection and treatment. Our goal is to determine if chest x-rays,computer aided detection (CAD)and a CT scan can detect disease earlier when treatment is more effective. If we improve the detection of disease, we will see if screening reduces the incidence of symptomatic advanced lung cancer relative to no screening in people at high risk to develop lung cancer.

Eligibility Criteria:
Inclusion Criteria:

* ages 40-75 years
* If ages 40-59, then one of the following criteria needs to be met:

  * Current or ex-smoker with \>25 pack years and a family history of lung cancer(parent or sibling) OR
  * current or ex-smoker with \> 25 pack years and COPD OR
  * current or ex-smoker with a \> 35 pack year history
* If ages 60-75, then one of the following additional criteria needs to be met:

  * Current or ex-smoker with \>25 pack years and a family history of lung cancer (parent or sibling) OR
  * Current or ex-smoker with \>25 pack years and COPD OR
  * Current or ex-smoker with a \>30 pack year history
* Subject is able to return to Cleveland Clinic for annual follow-up screening
* Subject is willing to sign a medical release form

Exclusion Criteria:

* Current health requires oxygen
* Have had a chest x-ray or CT of the chest within the last 6 months
* Previous pneumonectomy
* Lobectomy of the lung within the last 5 years
* Diagnosed malignancy within the last 5 years, excluding non-melanoma skin cancer, carcinoma in situ of the cervix and localized prostate cancer
* A medical condition that would prevent treatment for lung cancer
* Within the last 6 weeks, one of the following has occured:

  * A new cough or chronic cough that has gotten worse
  * Either new shortness of breath, or any worsening of shortness of breath
  * A cough producing blood
  * Constant chest pain
  * Respiratory infection, pneumonia, or cold
  * Unintentional and unexplained weight loss greater than 5% of total body weight
Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage

This study compares Aquacel against routine Iodoform packing for packing abscess cavities after incision and drainage. It is hypothesized that Aquacel will produce speedier healing of the abscess.

The large increase in the incidence of skin and soft tissue infections cause by methicillin resistant staphylococcus aureus (MRSA) has produced a corresponding increase in the number of ED patients presenting with abscesses that require incision and drainage. This study compares Aquacel against routine Iodoform packing for packing abscess cavities after incision and drainage. It is hypothesized that Aquacel will produce speedier healing of the abscess. More effective abscess healing will reduce the need for oral antibiotic coverage, which will in turn reduce the potential for drug resistance caused by indiscriminate use of oral antibiotics.

Eligibility Criteria:
Inclusion Criteria:

* presenting to Maricopa Medical Center ED with cutaneous abscess requiring incision and drainage

Exclusion Criteria:

* known sensitivity to Aquacel
* pregnant, nursing, or expecting to become pregnant
* incarcerated patient
* prior treatment of same abscess with incision and drainage
* multiple abscesses
* immunodeficiency
* facial abscess
* suspected osteomyelitis or septic arthritis
* diabetic foot, decubitis, or ischaemic ulcers
* unable to provide informed consent or assent
Rabies Treatment by Exposure of Patient to X-Ray

x-ray has been proven to kill Rabies virus in vitro, so the investigators can use it in treatment of rabies infected patients.

x-ray has been proven to kill Rabies virus in vitro, so the investigators can use it in treatment of rabies infected patients.

this can be done by exposure of infected , manifested patient who didn't receive prophylaxis or delayed in receiving immunoglobulins .

also can be applied to patients who have the injury in upper body near the CNS..

it's just an idea and the investigators need help to approve its effect and the investigators believe it will really work and give a new, rapid , cheap and very effective treatment to a 100% fatal disease..

the investigator also predict good results when x ray applied to some localized infections beside its current lines of treatment..

Eligibility Criteria:
Inclusion Criteria:

* patient bitten by rabid animal with signs and symptoms

Exclusion Criteria:

* bitten by non rabid animal
Spectrum of Bacterial Infections in Rheumatology

Retrospective study of patients with a proved non-tuberculous osteoarticular infection (OAI) diagnosed in a rheumatology department during the years 2010-2020. The objectives are :

* To describe sites, type of micro-organism, clinical data, origin of infection, therapeutic modalities et outcome
* To compare OAI of urinary origin with those with another origin

This retrospective study will be conducted on medical files. Patients will be mainly selected on :

* A proved osteoarticular infection (OAI) diagnosed in the department of rheumatology of the René Dubos hospital from 1° January 2010 to 31 December 2020.
* Adult patients 18 year's old or older
* Infection proved by positive culture in the osteoarticular site and/or blood (with typical clinical and imaging features)

The followed OAI are not included :

* Infection on prosthetic joint, materiel ; post-operative OAI ; osteomyelitis
* Brucellosis ; Lyme disease

Patients are selected from the codification of the hospitalization ; medical files are reviewed by the investigators.

OAI of urinary origin is defined either by the same micro-organism in urine and osteo-articular sample (or blood) or a bacteria in the osteo-articular sample in conjunction with : urologic pathology, recurrent urinary tract infection, urologic surgery, antibiotic therapy.

* Characteristics of three populations will be compared :
* - OAI of urinary origin
* - OAI of another origin (skin, etc)
* - OAI without known origin Characteristics include : gender, age, risk factors, site of osteo-articular infection, type of micro-organism, type of positive sample(s), blood cultures, urinary cultures, duration of symptoms, site of primary infection and/or type of contamination, biological results, echocardiography, imaging results, type of treatment (medical, surgical), outcome, duration of hospitalization, intensive unit care stay, death at hospital.

Eligibility Criteria:
Inclusion Criteria:

* Subject aged 18 years and over at the time of diagnosis
* Osteoarticular infection (septic arthritis, spondylodiscitis), by a bacterium or a fungus, proven by a bacteriological sample in situ or in the blood by positive blood culture (with an unequivocal clinical, biological and imaging feature),
* Diagnosed between 01/01/2010 and 12/31/2020 (11 years)
* Hospitalization in the rheumatology department of CH René Dubos, Pontoise

Exclusion Criteria:

* Bacterial infection due to the following germs: mycobacteria, brucella, Borrelia
* Early infection on joint prosthesis
* Peripheral osteomyelitis
* Osteoarticular infection without bacteriological proof
A Treatment for Depression Via a Gamified Mobile Phone Application Based on a New Cognitive Model

The study is a randomized controlled treatment study comparing changes in depressive symptoms over 8 weeks between individuals with Major Depressive Disorder (MDD) who have access to an FTP-based mobile phone application and a control group not engaging with the app. FTP, the process of Facilitating Thought Progression, trains the brain's cognitive thought process to expand, accelerate, and be more creative, to alleviate depressive symptoms.

This project aims to determine the effectiveness of an FTP-based mobile phone application in the alleviation of clinical symptoms of depression. In an attempt to change thought progression to be broader and more readily expansive, we had translated paradigms meant to expand thinking patterns into engaging mobile games. Our hypothesis is that the FTP-based mobile phone application will be able to decrease depressive clinical symptoms in a significant manner.

Participants meeting the inclusion criteria will be asked to play the app and undergo clinical and self-assessment evaluations regularly over the course of 8 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Consenting Adults, ages 20-50
* Able to read, understand and provide written informed consent in English
* Participants who are the sole users of an iPhone or an Android smartphone, and agree to download and use the digital mobile phone application as required by the protocol
* Participants who are comfortable using applications and games on their smartphones
* Participants with a current primary diagnosis of MDD or mild depression. MADRS≥15 and \<35
* Participants who are taking any medications which are FDA approved or used off-label for mood or anxiety should be on a stable dosage for the past 6 weeks and have no plan to change dosage during the 8 weeks they will be in the study
* Participants who are receiving therapy should have been with the same therapist for the previous 60 days and have no plan to change therapy protocol during the 8 weeks of the study

Exclusion Criteria:

* Participants who have plans to change their medications which are FDA approved or used off-label for mood or anxiety or their therapy protocol during the 8 weeks of the study
* Participants who have made any changes to their therapy protocol, including starting therapy, stopping therapy, or changing providers within the past 60 days
* Participants who have made any changes to medications which are FDA-approved or used off-label for mood or anxiety in the last 6 weeks
* Participants who have used a computer, web, or smartphone software-based application for mental health or depression in the last 6 weeks
* Being at imminent risk for Suicidal behavior (via MINI)

Note: Other protocol-defined exclusion criteria applied.
Sex-dependent Effects of Flavanols on Vascular Status

Epidemiological studies suggest that certain foods rich in flavanols, including cocoa products, red wine, and tea, are associated with decreased cardiovascular mortality and morbidity. Dietary interventional studies have corroborated this finding and showed that flavanols can acutely and after sustained ingestion improve surrogate markers of cardiovascular risk including endothelial function. Endothelial dysfunction is the key event in the development and progression of cardiovascular disease. The aim of the study is to assess sex specific effects of cocoa flavanols on endothelial and vascular function in healthy subjects.


Eligibility Criteria:
Inclusion Criteria:

* healthy post-menopausal femal subjects (\>50 years)
* healthy male subjects (\>50 years)

Exclusion Criteria:

* acute inflammation
* cardiac arrhythmia
* renal failure
* heart failure (NYHA II-IV)
* diabetes mellitus
* CRP \> 1 mg/dl
* malignant disease